TSX Exchange Symbol: RVX
CALGARY, Oct. 1, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) will be hosting a corporate update conference call and webcast on Monday, October 6, 2014 at 11 am MDT / 1 pm ET.
Details for the conference call and webcast are as follows:
Link to webcast: http://services.choruscall.ca/links/resverlogix141006.html
Dial in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340
About Resverlogix
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I. RVX-208 is a first-in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer’s disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix’s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
| Company Contacts: | |||
| Donald J. McCaffrey | Sarah Zapotichny | ||
| President and CEO | Director, Investor Relations | ||
| Resverlogix Corp. | Resverlogix Corp. | ||
| Phone: 403-254-9252 | Phone: 403-254-9252 | ||
| Email: don@resverlogix.com | Email: sarah@resverlogix.com | ||
SOURCE Resverlogix Corp.
Help employers find you! Check out all the jobs and post your resume.